行情

SNSS

SNSS

Sunesis Pharma
NASDAQ

实时行情|Nasdaq Last Sale

0.5573
-0.0127
-2.23%
盘后: 0.5700 +0.0127 +2.28% 19:20 01/17 EST
开盘
0.5839
昨收
0.5700
最高
0.6150
最低
0.5130
成交量
280.96万
成交额
--
52周最高
1.770
52周最低
0.1951
市值
6,203.86万
市盈率(TTM)
-1.3856
分时
5日
1月
3月
1年
5年

分析师评级

4位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

SNSS 新闻

  • Is Sunesis Pharmaceuticals, Inc. (SNSS) Going To Burn These Hedge Funds ?
  • Insider Monkey.2019/12/19 23:10
  • Sunesis Pharmaceuticals (SNSS) Investor Presentation - Slideshow
  • Seeking Alpha - Article.2019/12/11 17:28
  • The Week Ahead In Biotech: ASH Presentations Pick Up Steam, Correvio Awaits Adcom Ruling
  • Benzinga.2019/12/07 13:35
  • The Week Ahead In Biotech: ASH Presentations Pick Up Steam, Correvio Awaits Adcom Ruling
  • Benzinga.2019/12/07 13:35

更多

所属板块

生物技术和医学研究
-0.10%
制药与医学研究
+0.07%

热门股票

名称
价格
涨跌幅

SNSS 简况

Sunesis Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Company’s lead programs are Vecabrutinib, SNS-510 and TAK-580. The Company also offers Vosaroxin, an anticancer quinolone derivative (AQD), which is used for the treatment of acute myeloid leukemia (AML). Vecabrutinib is a selective, reversible, non-covalent binding inhibitor of Bruton's tyrosine kinase (BTK) inhibitors. SNS-510 is a phosphoinositide dependent protein kinase 1 (PDK1) inhibitors. TAK-580 is an oral, investigative drug selective for pan-Raf kinase inhibition, in patients with relapsed or refractory solid tumors.
展开

Webull提供Sunesis Pharmaceuticals, Inc.的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。